NUR 6011 Exam 1 Actual Exam V1 | NUR 6011 Advance Pharmacology
(NUR6011 Exam 1) | William Paterson University
1. Which pharmacokinetic parameter describes the percentage of a drug dose that reaches
the systemic circulation in an active form?
A. Bioavailability
B. Clearance
C. Volume of distribution
D. Half-life
Answer: A
Rationale: Bioavailability is the fraction of an administered drug that enters the systemic
circulation unchanged. Intravenous administration provides 100% bioavailability by
bypassing the digestive tract and first-pass hepatic metabolism. Understanding
bioavailability is crucial for calculating dosage transitions between oral and parenteral
routes.
2. When prescribing a drug that undergoes significant first-pass metabolism, which route of
administration should the Nurse Practitioner consider for maximum effect?
A. Oral
B. Enteric-coated tablet
C. Gastrostomy tube
D. Sublingual
Answer: D
Rationale: The sublingual route allows a drug to be absorbed directly into the systemic
circulation through the oral mucosa, bypassing the portal vein and liver. First-pass
metabolism occurs primarily when drugs are absorbed from the GI tract and pass through
the liver via the portal system before reaching the heart. By avoiding the liver initially,
higher concentrations of the active drug reach target tissues.
3. A patient with hypoalbuminemia is prescribed a highly protein-bound medication. What
clinical effect should the Nurse Practitioner anticipate?
A. Increased risk of drug toxicity
B. Decreased drug efficacy due to lack of transport
C. Shortened duration of drug action
D. Decreased renal excretion of the drug
,Answer: A
Rationale: Highly protein-bound drugs compete for binding sites on albumin; however,
only the ‘free’ or unbound drug is pharmacologically active. In patients with low albumin
levels, there are fewer binding sites, leading to a higher concentration of free drug in the
plasma. This increased free fraction can lead to toxic effects even if total drug levels appear
within a normal range.
4. A drug with a large volume of distribution (Vd) is most likely to have which characteristic?
A. High lipid solubility
B. High plasma concentration
C. Low tissue binding
D. Heavy protein binding in the blood
Answer: A
Rationale: A high volume of distribution indicates that the drug is extensively distributed
into peripheral tissues rather than remaining in the plasma. Lipophilic drugs easily cross
cell membranes and distribute into adipose tissue, resulting in a large Vd. Conversely,
drugs that are highly water-soluble or highly protein-bound tend to have a small Vd.
5. How many half-lives are typically required for a drug to reach steady-state concentration in
the plasma?
A. 1 to 2
B. 2 to 3
C. 7 to 10
D. 4 to 5
Answer: D
Rationale: Steady state is achieved when the rate of drug administration equals the rate of
drug elimination. It generally takes approximately 4 to 5 half-lives for a drug to reach this
plateau during continuous dosing. This principle is vital for determining when to measure
therapeutic drug levels to assess efficacy.
6. A patient is taking a medication that is a known CYP3A4 inducer. How will this affect
another drug metabolized by the same enzyme?
A. It will increase the plasma concentration of the second drug.
B. It will decrease the clearance of the second drug.
C. It will decrease the plasma concentration of the second drug.
D. It will have no effect on the second drug.
, Answer: C
Rationale: Enzyme induction occurs when a drug stimulates the synthesis of more
metabolic enzymes, such as CYP3A4. This leads to an increased rate of metabolism for any
substrate drugs that utilize the same pathway. Consequently, the plasma levels of the
substrate drug will drop, potentially leading to subtherapeutic effects and treatment
failure.
7. Which statement best describes the action of a competitive antagonist?
A. It binds to a different site than the agonist and changes the receptor shape.
B. It permanently binds to the receptor, preventing any agonist activity.
C. It binds to the same receptor site as the agonist but does not activate it.
D. It enhances the receptor’s affinity for the endogenous ligand.
Answer: C
Rationale: Competitive antagonists compete with agonists for the same binding site on a
receptor. They have affinity for the receptor but lack intrinsic activity, meaning they do not
trigger a biological response. The effect of a competitive antagonist can be overcome by
increasing the concentration of the agonist.
8. The therapeutic index (TI) of a drug is a ratio that compares:
A. The drug’s potency to its efficacy.
B. The peak level to the trough level.
C. The volume of distribution to the clearance rate.
D. The toxic dose to the effective dose.
Answer: D
Rationale: The therapeutic index is the ratio between the dose that causes toxicity (TD50)
and the dose that produces a therapeutic effect (ED50). A narrow therapeutic index means
that the margin between a safe dose and a toxic dose is small. Drugs with a narrow TI
require close clinical monitoring and frequent blood level checks.
9. In geriatric patients, what physiological change most significantly impacts the distribution
of lipid-soluble drugs?
A. Increased total body water
B. Increased serum albumin levels
C. Increased percentage of body fat
D. Increased gastric pH
Answer: C
(NUR6011 Exam 1) | William Paterson University
1. Which pharmacokinetic parameter describes the percentage of a drug dose that reaches
the systemic circulation in an active form?
A. Bioavailability
B. Clearance
C. Volume of distribution
D. Half-life
Answer: A
Rationale: Bioavailability is the fraction of an administered drug that enters the systemic
circulation unchanged. Intravenous administration provides 100% bioavailability by
bypassing the digestive tract and first-pass hepatic metabolism. Understanding
bioavailability is crucial for calculating dosage transitions between oral and parenteral
routes.
2. When prescribing a drug that undergoes significant first-pass metabolism, which route of
administration should the Nurse Practitioner consider for maximum effect?
A. Oral
B. Enteric-coated tablet
C. Gastrostomy tube
D. Sublingual
Answer: D
Rationale: The sublingual route allows a drug to be absorbed directly into the systemic
circulation through the oral mucosa, bypassing the portal vein and liver. First-pass
metabolism occurs primarily when drugs are absorbed from the GI tract and pass through
the liver via the portal system before reaching the heart. By avoiding the liver initially,
higher concentrations of the active drug reach target tissues.
3. A patient with hypoalbuminemia is prescribed a highly protein-bound medication. What
clinical effect should the Nurse Practitioner anticipate?
A. Increased risk of drug toxicity
B. Decreased drug efficacy due to lack of transport
C. Shortened duration of drug action
D. Decreased renal excretion of the drug
,Answer: A
Rationale: Highly protein-bound drugs compete for binding sites on albumin; however,
only the ‘free’ or unbound drug is pharmacologically active. In patients with low albumin
levels, there are fewer binding sites, leading to a higher concentration of free drug in the
plasma. This increased free fraction can lead to toxic effects even if total drug levels appear
within a normal range.
4. A drug with a large volume of distribution (Vd) is most likely to have which characteristic?
A. High lipid solubility
B. High plasma concentration
C. Low tissue binding
D. Heavy protein binding in the blood
Answer: A
Rationale: A high volume of distribution indicates that the drug is extensively distributed
into peripheral tissues rather than remaining in the plasma. Lipophilic drugs easily cross
cell membranes and distribute into adipose tissue, resulting in a large Vd. Conversely,
drugs that are highly water-soluble or highly protein-bound tend to have a small Vd.
5. How many half-lives are typically required for a drug to reach steady-state concentration in
the plasma?
A. 1 to 2
B. 2 to 3
C. 7 to 10
D. 4 to 5
Answer: D
Rationale: Steady state is achieved when the rate of drug administration equals the rate of
drug elimination. It generally takes approximately 4 to 5 half-lives for a drug to reach this
plateau during continuous dosing. This principle is vital for determining when to measure
therapeutic drug levels to assess efficacy.
6. A patient is taking a medication that is a known CYP3A4 inducer. How will this affect
another drug metabolized by the same enzyme?
A. It will increase the plasma concentration of the second drug.
B. It will decrease the clearance of the second drug.
C. It will decrease the plasma concentration of the second drug.
D. It will have no effect on the second drug.
, Answer: C
Rationale: Enzyme induction occurs when a drug stimulates the synthesis of more
metabolic enzymes, such as CYP3A4. This leads to an increased rate of metabolism for any
substrate drugs that utilize the same pathway. Consequently, the plasma levels of the
substrate drug will drop, potentially leading to subtherapeutic effects and treatment
failure.
7. Which statement best describes the action of a competitive antagonist?
A. It binds to a different site than the agonist and changes the receptor shape.
B. It permanently binds to the receptor, preventing any agonist activity.
C. It binds to the same receptor site as the agonist but does not activate it.
D. It enhances the receptor’s affinity for the endogenous ligand.
Answer: C
Rationale: Competitive antagonists compete with agonists for the same binding site on a
receptor. They have affinity for the receptor but lack intrinsic activity, meaning they do not
trigger a biological response. The effect of a competitive antagonist can be overcome by
increasing the concentration of the agonist.
8. The therapeutic index (TI) of a drug is a ratio that compares:
A. The drug’s potency to its efficacy.
B. The peak level to the trough level.
C. The volume of distribution to the clearance rate.
D. The toxic dose to the effective dose.
Answer: D
Rationale: The therapeutic index is the ratio between the dose that causes toxicity (TD50)
and the dose that produces a therapeutic effect (ED50). A narrow therapeutic index means
that the margin between a safe dose and a toxic dose is small. Drugs with a narrow TI
require close clinical monitoring and frequent blood level checks.
9. In geriatric patients, what physiological change most significantly impacts the distribution
of lipid-soluble drugs?
A. Increased total body water
B. Increased serum albumin levels
C. Increased percentage of body fat
D. Increased gastric pH
Answer: C
